Lupus Drug news: Benlysta looking good!
Check out these articles from the Washington Post and the New York Times - both touching on the promising outlook for Benlysta, Human Genome Sciences latest attempt at a lupus drug. Here's a snippet from the NYT article below - click on the links above to read the entire articles.
***
Trial for New Lupus Treatment Is Called Promising
by Andrew Pollack, Published: July 20, 2009
NYT
A medicine to treat lupus has proved effective in a large clinical trial, which could pave the way for approval of the first new treatment for the disease in more than 40 years. In recent years, many other companies have tried but failed to bring a lupus treatment to market
The success of the trial could lead to a rise in the shares of the drug’s developer, Human Genome Sciences, which will announce the results Monday morning. Almost all Wall Street analysts have been predicting the drug, known as Benlysta, would fail in the trial.
“For the one million people with lupus in the United States, this is nothing short of revolutionary,” said Dr. Daniel J. Wallace, a clinical professor of medicine at the University of California, Los Angeles, who was a consultant to Human Genome Sciences on the structure of the trial.
***
Trial for New Lupus Treatment Is Called Promising
by Andrew Pollack, Published: July 20, 2009
NYT
A medicine to treat lupus has proved effective in a large clinical trial, which could pave the way for approval of the first new treatment for the disease in more than 40 years. In recent years, many other companies have tried but failed to bring a lupus treatment to market
The success of the trial could lead to a rise in the shares of the drug’s developer, Human Genome Sciences, which will announce the results Monday morning. Almost all Wall Street analysts have been predicting the drug, known as Benlysta, would fail in the trial.
“For the one million people with lupus in the United States, this is nothing short of revolutionary,” said Dr. Daniel J. Wallace, a clinical professor of medicine at the University of California, Los Angeles, who was a consultant to Human Genome Sciences on the structure of the trial.
Comments
Reagrds.
Take care!
SG